Long COVID describes persistent multisystem symptoms (fatigue, dyspnoea, cognitive impairment, autonomic dysfunction) extending ≥12 weeks after acute SARS-CoV-2 infection.
Stem cell therapy for Long COVID is an investigational regenerative approach that uses living cells — such as mesenchymal stem cells and exosomes — to target the disease process. MSC and exosome protocols target the persistent inflammation and immune dysregulation behind long-COVID fatigue and brain-fog, as supportive care. It is not an approved cure for Long COVID: results come from early-phase clinical trials and clinic case series, not large randomised studies, and the realistic goal is slowed progression or symptom improvement rather than reversal.
Long COVID describes persistent multisystem symptoms (fatigue, dyspnoea, cognitive impairment, autonomic dysfunction) extending ≥12 weeks after acute SARS-CoV-2 infection. Proposed mechanisms include persistent viral fragments in reservoir tissues, endothelial activation with microclot formation, dysregulated immune memory (skewed Th1/Th17 responses, reduced regulatory T cells), and mitochondrial dysfunction. Placental mesenchymal stem cells and exosomes address these pathways through endothelial repair, anti-inflammatory cytokine secretion, and metabolic rescue of dysfunctional immune cells. Eleven registered clinical trials and two actively recruiting protocols evaluate MSC and exosome infusions in long-COVID cohorts, predominantly focusing on severe functional impairment or cardiopulmonary involvement.
| Indikative Kosten · Bulgarien (EU) | €3,000–€8,000 |
|---|---|
| Globale Marktkostenfalle | €2,700–€23,000 (placidway.com) |
| Wichtigste untersuchte Zelltypen | MSCs from Amniotic Membrane, Exosomes |
| Genehmigungsstatus | Experimentell |
| Registrierte Studien (ClinicalTrials.gov) | 11 · 2 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Published phase I safety data and small phase II trials (n=20–80 per arm) document symptomatic improvement in fatigue severity, exercise tolerance, and cognitive clarity in 40–55% of infused participants over 8–12 weeks. Objective markers—circulating microclot burden, endothelial dysfunction indices, IL-6 levels—show modest reduction in responder subgroups. One multicentre registry reports durable functional improvement (60-metre walk distance, sustained exertion capacity) persisting at 6 months in 45% of treated cohorts. Blinded controlled efficacy trials remain pending.
Depending on assessment, a Long COVID protocol may draw on:
Long-COVID MSC protocols in Sofia range €4,500–7,000 for treatment courses comprising 2–3 intravenous infusions over 6–12 weeks, alongside immunological and cardiopulmonary baseline assessment, post-treatment follow-up imaging (chest CT, echocardiography), and exercise tolerance testing. Specialised post-COVID clinics may charge facility and monitoring fees in addition to cell-preparation costs. International travel for treatment adds significantly to overall expense.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Long COVID cost-by-country breakdown, or compare the best countries for Long COVID →
Vor der Buchung prüfen: Sicherheit & Regulierung, das Erholungsklima, ob Sie geeignet sind, und welcher Zelltyp zu Long COVID passt.
Vollständiges Long COVID FAQ → · Long COVID Kostenaufschlüsselung →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Bin ich geeignet? · Welcher Zelltyp? · Types of clinics & best countries · Kostenrechner
Medizinisch geprüft vom Redaktionsteam von StemCellAtlas zusammen mit Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) der Partnerklinik Stem Plus (Sofia), gemäß ISSCR-, FDA- und EMA-Leitlinien. Last reviewed 2026-07-23; see our editorial standards. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung